AZTR
Azitra, Inc.·Healthcare
0.23
2.947%(−0.01)
Market ClosedLast Updated: — ET
52W L: $0.1052W H: $2.67
AZTR NEWS
benzinga.com
Mar 20
Why Are Shares Of Azitra Rising?
Azitra's spike is being fueled by a securities purchase agreement with healthcare-focused institutional investors for gross proceeds of up to $31.4 million, with Series B and C warrants exercisable at $0.123 per share and Series A convertible preferred priced at $1,000 per share.
feeds.benzinga.com
Mar 20
Azitra Inc. (AZTR) Surges Over 44% After Hours— Here's Why It's Trending
Azitra shares jumped over 44% in after-hours trading following a $31.4 million financing deal to advance its filaggrin protein and peptide platform.
prnewswire.com
Mar 19
Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million
Initial funding of approximately $10.5MM in convertible preferred stock and up to an additional $20.9MM upon cash exercise of warrants Financing marks launch of Azitra new innovative protein and peptide research programs for the cosmetic and cosmeceutical markets Leverages untapped potential of Azitra's genetic engineering platform to accelerate time to commercialization BRANFORD, Conn., March 19, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a securities purchase agreement (the "SPA") with new and existing healthcare focused institutional investors.
prnewswire.com
Mar 13
Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement
BRANFORD, Conn., March 13, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Azitra was not in compliance with the Exchange's continued listing standards under Section 1003(a)(iii) of the NYSE American Company Guide (the "Company Guide").
prnewswire.com
Mar 5
Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders
BRANFORD, Conn., March 5, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR) ("Azitra" or the "Company"), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has cancelled the Company's special meeting of stockholders that was originally scheduled for February 6, 2026, but was adjourned due to a lack of quorum until March 6, 2026.
prnewswire.com
Feb 27
Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates
BRANFORD, Conn., Feb. 27, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2025, and provided a business update.
